<DOC>
	<DOCNO>NCT00743483</DOCNO>
	<brief_summary>The purpose study evaluate efficacy patient cystic fibrosis pancreatic insufficiency follow treatment BSSL</brief_summary>
	<brief_title>Efficacy Bucelipase Alfa ( BSSL ) Patients With Cystic Fibrosis Pancreatic Insufficiency</brief_title>
	<detailed_description>In open study , patient enter baseline period 6 day pancreatic enzyme therapy discontinue standard diet give . After baseline period , patient enter treatment period 6 day fix dose BSSL administer . The primary efficacy measurement make collect stool last three day period .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Patients cystic fibrosis pancreatic insufficiency able refrain ongoing pancreatic enzyme treatment period 7 day able produce stool &gt; = 5 time per week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>pancreatic insufficiency</keyword>
	<keyword>bucelipase alfa</keyword>
	<keyword>bile salt stimulate lipase</keyword>
	<keyword>BSSL</keyword>
	<keyword>coefficient fat absorption</keyword>
</DOC>